QUIBRON-T SUMMARY
QUIBRON®-T (Theophylline Tablets USP) ACCUDOSE® Tablets IMMEDIATE-RELEASE BRONCHODILATOR
Theophylline is structurally classified as a methylxanthine.
Quibron®-T is available as tablets intended for oral administration, containing 300 mg of anhydrous theophylline per tablet. Quibron®-T is an oral bronchodilator in an immediate-release formulation in the ACCUDOSE® Tablet design. With functional trisects and bisects, Quibron®-T Tablets can be accurately divided into 100-, 150-, and 200-mg segments to provide a variety of dosing increments, as required.
Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
|
NEWS HIGHLIGHTSMedia Articles Related to Quibron-T (Theophylline)
Asthma Increases Risk for Periodontitis Source: Medscape Allergy & Clinical Immunology Headlines [2017.09.25] People with asthma should pay particularly close attention to their oral health after research found a strong link between the condition and gum disease. WebMD Health News
Could Pests, Dust Lower Kids' Odds for Asthma? Source: MedicineNet Allergy Specialty [2017.09.22] Title: Could Pests, Dust Lower Kids' Odds for Asthma? Category: Health News Created: 9/21/2017 12:00:00 AM Last Editorial Review: 9/22/2017 12:00:00 AM
Asthma Drug Tied to Nightmares, Depression Source: MedicineNet Allergy Specialty [2017.09.22] Title: Asthma Drug Tied to Nightmares, Depression Category: Health News Created: 9/21/2017 12:00:00 AM Last Editorial Review: 9/22/2017 12:00:00 AM
Kids' Colds Linked to Asthma, Lung Problems Later Source: MedicineNet Adenoids and Tonsils Specialty [2017.09.20] Title: Kids' Colds Linked to Asthma, Lung Problems Later Category: Health News Created: 9/19/2017 12:00:00 AM Last Editorial Review: 9/20/2017 12:00:00 AM
Asthma Quiz: Test Your Medical IQ Source: MedicineNet Asthma Complexities Specialty [2017.09.19] Title: Asthma Quiz: Test Your Medical IQ Category: MedicineNet Quiz Created: 6/3/2011 4:21:00 PM Last Editorial Review: 9/19/2017 6:36:12 PM
Published Studies Related to Quibron-T (Theophylline)
Beneficial effects of theophylline infusions in surgical patients with intra-abdominal hypertension. [2011.08] BACKGROUND: Intra-abdominal hypertension (IAH) can cause high mortality. Recently, we found that IAH was associated with increased serum levels of adenosine and interleukin 10. Our present "hypothesis-generated study" was based on the above mentioned results... CONCLUSIONS: Adenosine receptor antagonism with T following IAH diagnosis resulted in markedly reduced mortality in patients with moderated IAH (<20 mmHg). Theophylline-associated mortality reduction may be related to improved renal perfusion and improved MAP, presumably caused by adenosine receptor blockade. Because this study was not a randomized controlled study, these compelling observations require further multicentric clinical confirmation.
Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults. [2011.07] OBJECTIVE: To investigate whether a pharmacokinetic drug-drug interaction exists between theophylline (THEO), a CYP1A2 substrate with a narrow therapeutic index, and the concomitant substrate roflumilast (ROF), a novel selective PDE4 inhibitor partially metabolized by CYP1A2... CONCLUSIONS: Neither ROF nor its main metabolite had any impact on the metabolism of the concomitant CYP1A2 substrate THEO in humans. Though co-administration of THEO resulted in a minor increase (28%) in total ROF exposure, no safety or tolerability concerns and no altered total PDE4 inhibition of both ROF and R-NO, were observed.
Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. [2010.11] Although the optimal strategy for preventing contrast-induced acute kidney injury (CI-AKI) has not yet been established, the current strategy focuses on adequate periprocedural hydration, the use of a low amount of low or iso-osmolar contrast medium, and the application of adjunctive therapies, including hemofiltration, hemodialysis and drugs...
Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. [2010.09.29] Although the optimal strategy for preventing contrast-induced acute kidney injury (CI-AKI) has not yet been established, the current strategy focuses on adequate periprocedural hydration, the use of a low amount of low or iso-osmolar contrast medium, and the application of adjunctive therapies, including hemofiltration, hemodialysis and drugs...
Adenosine receptor inhibition with theophylline attenuates the skin blood flow response to local heating in humans. [2010.09] Mechanisms underlying the robust cutaneous vasodilatation in response to local heating of human skin remain unresolved. Adenosine receptor activation has been shown to induce vasodilatation via nitric oxide, and a substantial portion of the plateau phase to local heating of human skin has been shown to be dependent on nitric oxide...
Clinical Trials Related to Quibron-T (Theophylline)
The Effect of Theophylline in the Treatment of Bronchiectasis [Completed]
Theophylline was well recommended in the treatment of chronic obstructive pulmonary disease
(COPD) and asthma. However, there is no supporting evidence for their efficacy in the
treatment of bronchiectasis. Our hypothesis is that theophylline will play a role in
bronchiectasis. Our purpose is to examine the efficacy and safety of 24 weeks treatment with
theophylline in subjects with non-cystic fibrosis bronchiectasis.
Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study [Recruiting]
The aim of this multi-centre, double blind, randomised, controlled trial (DBRCT) is to
assess the effect of low dose theophylline, singly and in combination with low dose oral
prednisone, on COPD (Chronic Obstructive Pulmonary Disease) exacerbations, quality of life
and secondary clinical outcomes compared with usual therapy and placebo over 48 weeks of
treatment. Approximately 2400 symptomatic patients with COPD will be recruited in China for
comparison of low dose theophylline versus placebo and low dose theophylline + low dose
prednisone The primary end-point for this study is the difference between the three
treatment groups in
- COPD exacerbation rate
- Time to first severe exacerbation requiring hospitalisation or death
The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis [Completed]
The purpose of this study is to examine the efficacy and safety of 24 weeks treatment with
theophylline plus low-dose formoterol-budesonide in subjects with bronchiectasis.
Drug Interaction Study of Colchicine and Theophylline [Completed]
Colchicine is a supressor of hepatic CYP1A2 and theophylline is a sensitive CYP1A2 probe
substrate. When the two are co-administered the potential exists for a clinically
significant drug interaction. This study aims to determine the effect of steady-state
colchicine on the pharmacokinetics of theophylline administered as a single dose. A
secondary goal is to evaluate the safety and tolerability of this regimen in healthy
volunteers. All study subjects will be monitored for adverse events throughout the entire
study period.
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline [Recruiting]
This study is to determine the use of theophylline in patients with NSCLC and advanced solid
malignancies and whether treatment with theophylline will help lower or diminish the side
effect of diarrhea in patients taking erlotinib. Patients will be enrolled in one of two
parts of the study to verify the lowest dose of theophylline that is effective and the
highest dose of erlotinib that can be tolerated with theophylline. If this study shows that
theophylline is able to inhibit erlotinib induced diarrhea, it will help demonstrate that
patients using the tyrosine kinase inhibitor (TKIs), erlotinib, can use it effectively at
higher doses without experiencing severe diarrhea.
|